Steve Chang, MD
Ophthalmology · Reno, NVNPI 1801986625
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 49.2% of the total. Reporting peaked in 2019 at $32,409 and has fallen 95.2% since, to $1,560 in 2025. Among ophthalmology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $288.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$37K
- Alcon$25K
- Rxsight Inc$9K
- Johnson & Johnson Surgical Vision, Inc.$678
- Eyepoint US, Inc.$619
- Glaukos Corporation$534
- plus $1K from 14 others
What the payments were for
- Consulting fees$15,35521%
- Speaking & faculty fees$39,61153%
- Travel & lodging$7,87611%
- Food & beverage$11,79316%
- Gifts$190%
- Entertainment$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 48 | $36,719 |
| Alcon | 119 | $25,428 |
| Rxsight Inc | 26 | $9,491 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $678 |
| Eyepoint US, Inc. | 2 | $619 |
| Glaukos Corporation | 9 | $534 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $269 |
| Rayner Intraocular Lenses Limited | 12 | $224 |
| Amgen | 4 | $117 |
| Bausch Health US, LLC | 1 | $102 |
| Omeros Corporation | 7 | $102 |
| Hoffmann-la Roche Limited | 1 | $99 |
| Sight Sciences, Inc. | 2 | $94 |
| Staar Surgical Company | 3 | $78 |
| AbbVie | 2 | $49 |
| Bausch & Lomb Americas Inc. | 1 | $28 |
| Biotissue Holdings Inc. | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
| Tarsus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BROMSITE$29,854
- Clareon$9,123
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$8,082
- AcrySof IQ VIVITY IOL$7,105
- CEQUA$6,066
- AcrySof IQ VIVITY$4,283
- AcrySof IQ PanOptix$4,165
- RXSIGHT CONTACT LENS$780
- RXSIGHT INJECTOR CARTRIDGE$780
- RXSIGHT INJECTOR HANDPIECE$780
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$780
- DEXYCU$600
- LIGHT ADJUSTABLE LENS (LAL)$407
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$373
- Centurion$358
- AcrySof IQ PanOptix UV IOL$353
- Clareon PanOptix Pro$233
- iDose$186
- Tecnis Multifocal Family of 1-piece IOLS$139
- ARGOS$133
How this compares
$74,707 in reported general payments places this provider in the 95th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 16 | $10,413 |
| Atropine Sulfate | 61 | $1,293 |
| Latanoprost | 99 | $963 |
| Prednisolone Acetate | 13 | $478 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 11 | $71 |
| Timolol Maleate | 20 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $49 | $10,41316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Reno
- Arshad KhananiReno$2M
- Matthew MillsReno$15K
- Elena GeraymovychReno$14K
- Jamison EngleReno$6K
- Kevin GamettReno$6K
- Caleb MorrisReno$4K
- William DurantReno$4K
- Hardeep DhindsaReno$3K
- Peter FreemanReno$3K
- Xintong LiReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.